Oric Pharmaceuticals (ORIC) Equity Average (2019 - 2026)
Oric Pharmaceuticals filings provide 8 years of Equity Average readings, the most recent being $400.0 million for Q1 2026.
- Quarterly Equity Average rose 72.82% to $400.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $400.0 million through Mar 2026, up 72.82% year-over-year, with the annual reading at $313.7 million for FY2025, 34.3% up from the prior year.
- Equity Average hit $400.0 million in Q1 2026 for Oric Pharmaceuticals, up from $395.6 million in the prior quarter.
- Across five years, Equity Average topped out at $400.0 million in Q1 2026 and bottomed at $212.6 million in Q1 2023.
- Average Equity Average over 5 years is $276.3 million, with a median of $258.6 million recorded in 2024.
- The largest annual shift saw Equity Average dropped 22.56% in 2022 before it soared 72.82% in 2026.
- Oric Pharmaceuticals' Equity Average stood at $218.6 million in 2022, then rose by 7.85% to $235.8 million in 2023, then increased by 9.67% to $258.6 million in 2024, then skyrocketed by 53.02% to $395.6 million in 2025, then rose by 1.09% to $400.0 million in 2026.
- Per Business Quant, the three most recent readings for ORIC's Equity Average are $400.0 million (Q1 2026), $395.6 million (Q4 2025), and $365.5 million (Q3 2025).